PET/CT SUV_(max)值、核抗原Ki-67与淋巴瘤分期之间的相关性探讨  

A Study of Correlations Between PET/CT SUV_(max)、Nuclear Antigen Ki-67 and Staging of Lymphoma

作　　者：高海燕[1] 宋文忠[1] 谢红军[1] 刘浩[1] 刘兆辉[1] 

机构地区：[1]四川省人民医院核医学科,四川成都610072

出　　处：《中国医学影像学杂志》2010年第3期285-288,共4页Chinese Journal of Medical Imaging

摘　　要：目的:探讨PET/CT SUVmax值、核抗原Ki-67与淋巴瘤分期间的相互关系。材料与方法:对39例具有18F-FDG PET/CT资料和免疫组化资料(Ki-67)但未行治疗的淋巴瘤患者进行回顾性分析。根据临床综合评价对所有患者进行Ann Arbor分期,由计算机工作站获得每个病灶的SUVmax,随访时间6～41个月。为扩大样本量,本文将Ⅰ、Ⅱ、Ⅲ、Ⅳ期合为早期(Ⅰ期～Ⅱ期)、晚期(Ⅲ期～Ⅳ期)两组,通过BinaryLogistic回归分析探讨SUVmax值、Ki-67指数与早晚分期之间的关系,以Spearman相关分析观察SUVmax值和Ki-67指数之间的相关性及其密切程度。结果:①回归分析结果显示SUVmax值与淋巴瘤分期无关(P=0.163);Ki-67指数与淋巴瘤早、晚分期显著相关(P<0.001),且Ki-67指数越高,分期越趋向晚期。②由相关分析得出,SUVmax值和Ki-67指数之间呈显著正相关(P<0.001),但关系不密切(相关系数为0.251)。结论:Ki-67指数与淋巴瘤临床分期之间、SUVmax与Ki-67指数之间均成显著正相关。Objiective To discuss the correlations between PET/CT SUVmax,nuclear antigen Ki-67 and staging of Lymphoma.Meterials and methods 39 patients without treatment were retrospectively analyzed.All the patients have PET/CT datas and Ki-67 index in the immunohistochemistry.All the positive or negtive lesions were ascertained by the clinical evaluation,so that the staging was undertaken according to Ann Arbor method,and calculated the mean SUVmax of every patient。The follow-up time was 6～41 months.the relationships between PET/CT SUVmax,Ki-67 index and staging of Lymphoma were tested by Binary Logistic,and the relationship between PET/CT SUVmax and Ki-67 index by Spearman＇s correlation.Results ①There was no correlation between SUVmax and staging（P=0.163）;while there was a correlation（P0.001）between Ki-67 index and staging,the higher the index was,the more advanced the staging was.② The result of Spearman＇s correlation showed there was a significant positive correlation between SUVmax and Ki-67 index（P0.001）,but the relationship was not intimate enough with the coefficient 0.251.Conclusion there was a significant positive correlation between Ki-67 index and staging,as well as between SUVmax and Ki-67.

关 键 词：淋巴瘤 KI-67抗原 氟脱氧葡萄糖F18 正电子发射断层显像术 标准化摄取值 

分 类 号：R733.410.454[医药卫生—肿瘤]